



Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes

Diabetes Care 2017;40:1787–1789 | <https://doi.org/10.2337/dc17-1528>

Matthew J. Crowley,^{1,2}
John W. Williams Jr.,^{1,3}
Andrzej S. Kosinski,⁴ David A. D'Alessio,²
and John B. Buse⁵

OBJECTIVE

To explore prevalent metformin use as a potential moderator of the cardiovascular effects of dipeptidyl peptidase 4 inhibitors (DPP-4i).

RESEARCH DESIGN AND METHODS

We performed a meta-analysis of the three major cardiovascular outcomes trials examining DPP-4i. We used meta-regression to examine how the cardiovascular effects of DPP-4i differ between prevalent metformin users and baseline nonusers.

RESULTS

While prevalent metformin users experienced a trend toward improved cardiovascular outcomes with DPP-4i (summary hazard ratio [HR] 0.92 [95% CI 0.84, 1.01]), baseline metformin nonusers showed a trend toward harm (HR 1.10 [95% CI 0.97, 1.26]). The difference in overall DPP-4i effect between metformin user and nonuser subgroups was statistically significant ($P = 0.036$).

CONCLUSIONS

Baseline metformin status may have a moderating effect on cardiovascular outcomes with DPP-4i use. This hypothesis-generating analysis suggests there is residual uncertainty as to how DPP-4i affect cardiovascular outcomes, depending on concurrently prescribed medications.

Dipeptidyl peptidase 4 inhibitors (DPP-4i), which are often added to background metformin therapy as next-line agents for type 2 diabetes, appear to have a neutral effect on cardiovascular outcomes relative to placebo (1–3). However, subgroup analyses of recent cardiovascular outcomes trials (CVOTs) suggest that baseline metformin use may serve as a moderator of the effectiveness of DPP-4i. Among prevalent metformin users, each of the three major DPP-4i CVOTs reported a trend toward better cardiovascular outcomes with DPP-4i; by contrast, each study reported a trend toward poorer outcomes with DPP-4i among baseline nonusers of metformin. Two of these studies reported a significant or near-significant interaction between baseline metformin status and DPP-4i status for the primary outcome (1,2). In order to further explore prevalent metformin use as a potential moderator of the cardiovascular effects of DPP-4i, we conducted a stratified meta-analysis of the three major DPP-4i CVOTs (1–3).

RESEARCH DESIGN AND METHODS

This analysis focused on three recently published CVOTs examining agents in the DPP-4i class (1–3). Each study's supplementary appendix reported relevant data for the subgroups of prevalent metformin users and baseline nonusers,

¹Durham Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC

²Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University School of Medicine, Durham, NC

³Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC

⁴Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC

⁵Division of Endocrinology & Metabolism, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC

Corresponding author: Matthew J. Crowley, matthew.crowley@dm.duke.edu.

Received 25 July 2017 and accepted 20 September 2017.

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

including the number of patients in each subgroup, a hazard ratio (HR) for the primary composite study outcome associated with DPP-4i use in each subgroup, and a 95% CI for each subgroup HR.

Because these studies had good conceptual homogeneity in their design, populations, interventions, and outcomes, we performed quantitative synthesis using a DerSimonian-Laird random-effects model (4). As this analysis included only three studies, we conservatively used the Knapp-Hartung approach to adjust the SE of the estimated coefficients (5). In meta-analyses of ≤ 5 studies, the Knapp-Hartung approach is associated with acceptably low rates of type I error compared with the DerSimonian-Laird approach, particularly when studies are reasonably similar in size (as is the case in this analysis) (6). We performed meta-regression with metformin status as a covariate to establish the statistical significance of the difference in overall DPP-4i effect between prevalent metformin users and baseline nonusers. Subgroup summary HRs and 95% CIs were based on estimates from this meta-regression model. We evaluated statistical heterogeneity using Cochran Q and I^2 statistics. All quantitative analyses were performed using R (version 3.1.2), including R package “metafor” (version 1.9-7) for meta-analysis.

RESULTS

This analysis included three large, multinational trials, each of which randomized patients to receive a DPP-4i agent or placebo in addition to their existing diabetes therapy. Two studies exclusively included patients with known cardiovascular disease (1,2), while the third included patients with either established cardiovascular disease or multiple risk factors. Each study examined a particular DPP-4i agent: sitagliptin (1), alogliptin (2), or saxagliptin (3). The primary composite outcome for each of these studies comprised cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, with one study additionally including hospitalization for unstable angina (1). Only primary composite outcome data were presented by metformin subgroup. Median follow-up duration ranged from 1.5 to 3 years.

For the overall analytic population, DPP-4i had a neutral summary effect on the primary outcome (summary HR 0.99 [95% CI 0.87, 1.13]). However, prevalent metformin users (Fig. 1) experienced a trend toward reduction in the incidence of the primary study outcome with DPP-4i (summary HR 0.92 [95% CI 0.84, 1.01]). Individual study effects were consistent (Cochran $Q P = 0.37, I^2 = 0.0\%$). By contrast, the baseline metformin nonusers showed a trend toward harm with DPP-4i (HR 1.10 [95% CI 0.97, 1.26]). Individual

study effects were again consistent (Cochran $Q P = 0.75, I^2 = 0.0\%$).

Using meta-regression, the difference in overall DPP-4i effect between prevalent metformin users and baseline nonusers was statistically significant ($P = 0.036$), indicating a difference in the relative effects of DPP-4i based on metformin status.

CONCLUSIONS

This stratified meta-analysis of three major DPP-4i CVOTs shows that baseline metformin status may be a moderator of the effect of DPP-4i on cardiovascular outcomes. Consistent with prior analyses (7), DPP-4i use had a neutral effect on the primary composite outcome in the overall population; however, prevalent users of metformin experienced a trend toward reduction of cardiovascular events with DPP-4i, while baseline nonusers showed a trend toward harm. This difference in the overall effect of DPP-4i between metformin user and nonuser subgroups was statistically significant, suggesting that the cardiovascular effects of DPP-4i agents may differ depending on whether these medications are coprescribed with metformin.

Because newer medication classes like DPP-4i are typically added to background metformin therapy (8), metformin’s impact on the effectiveness of next-line drugs is of great interest. Currently, how diabetes medication classes interact to




Figure 1—Forest plot depicting the effect of DPP-4i on primary composite study outcomes, stratified by metformin user/nonuser subgroups ($P = 0.036$ for difference in DPP-4i effect between prevalent metformin users and baseline nonusers). N = number of patients.

affect cardiovascular outcomes is not well understood. This hypothesis-generating analysis suggests that there is residual uncertainty as to whether DPP-4i are associated with cardiovascular neutrality, benefit, or even harm, depending on how these medications are used in clinical practice.

Prevalent metformin users showed a trend toward improved cardiovascular outcomes with DPP-4i in this analysis. One physiologic mechanism by which metformin could potentiate the effectiveness of DPP-4i is via glucagon-like peptide 1 (GLP-1); metformin raises GLP-1 levels (9,10), and DPP-4i act by inhibiting GLP-1 degradation. It is therefore plausible that these drugs could interact synergistically. Baseline nonusers of metformin showed a trend toward poorer outcomes with DPP-4i, raising the possibility that off-target effects may outweigh any benefits of DPP-4i use in the absence of metformin.

While the effect of DPP-4i differed significantly between prevalent metformin users and baseline nonusers, metformin use is likely not the sole difference between these subgroups. For example, metformin use may be a marker for baseline differences in rates of chronic kidney disease or congestive heart failure, for which this analysis does not account. For this reason, it is possible that metformin use itself does not mediate the observed difference in DPP-4i effect between metformin users and nonusers. Subsequent analyses should incorporate statistical adjustment

for other population differences through use of patient-level data and should seek to assess available outcome measures individually rather than relying on composite outcomes.

We chose to focus exclusively on the three major DPP-4i CVOTs because these studies enrolled similar populations, used similar primary outcomes, and all reported data on metformin subgroups. The low heterogeneity on our stratified meta-analyses attests to these studies' similarity. Of note, specific agents within the DPP-4i class may interact with metformin differently. Future research should further examine metformin's moderating effects on individual DPP-4i agents and also explore how metformin may interact with other novel medication classes, such as GLP-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.

In summary, this hypothesis-generating analysis suggests that baseline metformin status may have a moderating effect on cardiovascular outcomes with DPP-4i use. These novel findings have great import for clinical application of DPP-4i and suggest intriguing areas for future investigation relating to DPP-4i and other diabetes medication classes.

Funding. M.J.C. is supported by a Career Development Award (CDA 13-261) from the U.S. Department of Veterans Affairs Health Services Research & Development Service.

The views expressed in this article are those of the authors and do not necessarily represent the views of the U.S. Department of Veterans Affairs.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

References

1. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2015;373:232–242
2. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med* 2013;369:1327–1335
3. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med* 2013;369:1317–1326
4. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–188
5. Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. *Stat Med* 2003;22:2693–2710
6. Int'Hout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol* 2014;14:25
7. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. *Cardiovasc Ther* 2014;32:147–158
8. American Diabetes Association. *Standards of Medical Care in Diabetes—2017*. *Diabetes Care* 2017;40:S1–S135
9. Kårhus ML, Brønden A, Sonne DP, Vilsbøll T, Knop FK. Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: a review. *Diabetes Obes Metab* 2017;19:1214–1222
10. Bahne E, Hansen M, Brønden A, Sonne DP, Vilsbøll T, Knop FK. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. *Diabetes Obes Metab* 2016;18:955–961